ResMed stock has delivered a 36.4% gain over the past three years, yet the current share price still screens as cheap relative to an intrinsic value estimate from a Discounted Cash Flow (DCF) model and to market based multiples.

• Over the last three years ResMed has returned 36.4%, which puts recent weakness into context for anyone focused on longer holding periods.
• The latest pullback followed softer longer term revenue expectations linked to suspended ventilator sales and cost pressures. This can help reset expectations but also adds uncertainty around future cash flows.
• On Simply Wall St's broader checks ResMed is assessed as undervalued in 5 of 6 tests, which points to a generally supportive read on valuation rather than a stretched one.

The issue now is whether the current discount to intrinsic value and earnings based metrics gives investors enough compensation for the risks that showed up in the recent outlook commentary.

Does ResMed Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) approach estimates what ResMed is worth based on the cash it is expected to generate for shareholders. ResMed produced around $1.66b in free cash flow over the last twelve months, and the model assumes that free cash flow continues to grow from this base rather than relying on a sharp rebound or steep decline.

On these cash flow projections, the DCF points to an estimated intrinsic value of about $325 per share, which is well above the current share price and implies the stock is 32.2% undervalued. The recent Class 1 recall and softer FY27 revenue outlook help explain why the market price has been held back, even though the cash flow profile used in the model still supports a higher value.

On balance, the DCF workup suggests ResMed stock currently appears undervalued relative to the cash it is expected to generate.

Our Discounted Cash Flow (DCF) analysis suggests ResMed is undervalued by 32.2%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Is ResMed a Bargain on Earnings?

The P/E ratio is a useful metric for ResMed because earnings are a key focus for mature, profitable medical equipment companies. ResMed currently trades on a P/E of about 20.9x, which is below both the Medical Equipment industry average of roughly 26.0x and the peer group average of 28.9x. According to Simply Wall St's model, a fair P/E for ResMed is around 26.3x based on its profile, which is higher than where the stock is priced today.

This gap suggests the market is applying a discount to ResMed relative to what the tailored fair multiple implies. The softer FY27 outlook and ventilator recall help explain some caution, yet the current P/E still comes in below both industry and peer benchmarks as well as the fair ratio.

On this earnings multiple, ResMed stock appears inexpensive compared to both its sector and the fair P/E estimate.

The ResMed Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the ResMed valuation puzzle leaves off and spell out which combinations of future growth, margins and earnings would need to hold for the stock to be worth materially more or less than today. Each narrative presents ResMed's fair value as a thesis about the business that can be revisited over time, rather than a one off snapshot, and these are available on Simply Wall St's Community page.

Community views on ResMed are split, with one camp focused on underappreciated sleep health demand and another worried about device supply and valuation risk.

Bull case: 11% undervalued

"Acceleration in adoption of home-based, cloud-connected therapy solutions and digital health platforms (including software like Brightree and AirView) enhances recurring high-margin revenue streams and increases both user retention and net profit margins over time..."

Bear case: 26% overvalued

"GLP-1 therapies are being framed internally as a once-in-a-generation demand opportunity. However, if broader weight loss adoption or new clinical data leads to fewer patients requiring CPAP, growth in device and mask revenue could fall short of current expectations and pressure earnings..."

Do you think there's more to the story for ResMed? Head over to our Community to see what others are saying!

The Bottom Line

ResMed screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and on earnings based multiples, so the market is already pricing in a fair amount of caution. That discount exists alongside real questions about longer term demand, product issues and cost pressures. The key debate from here is whether ResMed can sustain attractive cash generation and earnings power despite these headwinds. If that holds, today’s gap between price and intrinsic value could represent mispricing rather than a value trap.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.